Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

George B Rodrigues

Showing results (51-60 of 81) with videos related to

Pageof 9
Sort By:
BMC Cancer|July 25, 2012
Stereotactic ablative radiotherapy for comprehensive treatment of oligometastatic tumors (SABR-COMET): study protocol for a randomized phase II trialDavid A Palma, Cornelis J A Haasbeek, George B Rodrigues, et al.
BMC Cancer|October 10, 2020
Is hypofractionated whole pelvis radiotherapy (WPRT) as well tolerated as conventionally fractionated WPRT in prostate cancer patients? The HOPE trialLucas C Mendez, Andrew J Arifin, Glenn S Bauman, et al.
JAMA Oncology|February 24, 2022
Palliative Radiation for Advanced Central Lung Tumors With Intentional Avoidance of the Esophagus (PROACTIVE): A Phase 3 Randomized Clinical TrialAlexander V Louie, Patrick V Granton, Alysa Fairchild, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|November 2, 2023
What is the predictive value of RECIST criteria following stereotactic lung radiation?Stephanie Gulstene, Pencilla Lang, X Melody Qu, et al.
BMC Cancer|December 16, 2014
Functional lung avoidance for individualized radiotherapy (FLAIR): study protocol for a randomized, double-blind clinical trialDouglas A Hoover, Dante Pi Capaldi, Khadija Sheikh, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|November 9, 2020
American Radium Society Appropriate Use Criteria: Radiation Therapy for Limited-Stage SCLC 2020Stephen G Chun, Charles B Simone, Arya Amini, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|October 4, 2020
American Radium Society Appropriate Use Criteria on Radiation Therapy for Extensive-Stage SCLC, Kristin A Higgins, Charles B Simone, et al.
Thoracic Cancer|May 25, 2022
The quality of life in neoadjuvant versus adjuvant therapy of esophageal cancer treatment trial (QUINTETT): Randomized parallel clinical superiority trialRichard A Malthaner, Edward Yu, Michael Sanatani, et al.
International Journal of Radiation Oncology, Biology, Physics|September 27, 2021
American Radium Society Appropriate Use Criteria for Radiation Therapy in Oligometastatic or Oligoprogressive Non-Small Cell Lung CancerArya Amini, Vivek Verma, Charles B Simone, et al.
Radiation Oncology (London, England)|January 29, 2017
Short report: interim safety results for a phase II trial measuring the integration of stereotactic ablative radiotherapy (SABR) plus surgery for early stage non-small cell lung cancer (MISSILE-NSCLC)David A Palma, Timothy K Nguyen, Keith Kwan, et al.
Pageof 9

Showing results (51-60 of 81) with videos related to

Sort By:
Pageof 9
BMC Cancer|July 25, 2012
Stereotactic ablative radiotherapy for comprehensive treatment of oligometastatic tumors (SABR-COMET): study protocol for a randomized phase II trialDavid A Palma, Cornelis J A Haasbeek, George B Rodrigues, et al.
BMC Cancer|October 10, 2020
Is hypofractionated whole pelvis radiotherapy (WPRT) as well tolerated as conventionally fractionated WPRT in prostate cancer patients? The HOPE trialLucas C Mendez, Andrew J Arifin, Glenn S Bauman, et al.
JAMA Oncology|February 24, 2022
Palliative Radiation for Advanced Central Lung Tumors With Intentional Avoidance of the Esophagus (PROACTIVE): A Phase 3 Randomized Clinical TrialAlexander V Louie, Patrick V Granton, Alysa Fairchild, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|November 2, 2023
What is the predictive value of RECIST criteria following stereotactic lung radiation?Stephanie Gulstene, Pencilla Lang, X Melody Qu, et al.
BMC Cancer|December 16, 2014
Functional lung avoidance for individualized radiotherapy (FLAIR): study protocol for a randomized, double-blind clinical trialDouglas A Hoover, Dante Pi Capaldi, Khadija Sheikh, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|November 9, 2020
American Radium Society Appropriate Use Criteria: Radiation Therapy for Limited-Stage SCLC 2020Stephen G Chun, Charles B Simone, Arya Amini, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|October 4, 2020
American Radium Society Appropriate Use Criteria on Radiation Therapy for Extensive-Stage SCLC, Kristin A Higgins, Charles B Simone, et al.
Thoracic Cancer|May 25, 2022
The quality of life in neoadjuvant versus adjuvant therapy of esophageal cancer treatment trial (QUINTETT): Randomized parallel clinical superiority trialRichard A Malthaner, Edward Yu, Michael Sanatani, et al.
International Journal of Radiation Oncology, Biology, Physics|September 27, 2021
American Radium Society Appropriate Use Criteria for Radiation Therapy in Oligometastatic or Oligoprogressive Non-Small Cell Lung CancerArya Amini, Vivek Verma, Charles B Simone, et al.
Radiation Oncology (London, England)|January 29, 2017
Short report: interim safety results for a phase II trial measuring the integration of stereotactic ablative radiotherapy (SABR) plus surgery for early stage non-small cell lung cancer (MISSILE-NSCLC)David A Palma, Timothy K Nguyen, Keith Kwan, et al.
Pageof 9